Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 8968756
Fabrication of biscrolled fiber using carbon nanotube sheet
granted -
US 8968703
13C-MR detection using hyperpolarised 13C-fructose
granted -
US 8968699
Switchable nano-vehicle delivery systems, and methods for making and using them
granted -
US 8969321
Medical and nutritional applications of highly refined cellulose
granted -
US 8962038
Nitrite formulations and their use as nitric oxide prodrugs
granted -
US 8961959
Glucosylceramide synthase inhibitors and therapeutic methods using the same
granted -
US 8961982
Modulation of developmental immune programming and protection against cardiovascular disease, diabetes, infectious diseases, and cancer
granted -
US 8962709
Resin systems for dental restorative materials and methods using same
granted -
US 8962663
Small molecule inhibitors of the pleckstrin homology domain and methods for using same
granted -
US 8962569
Compositions comprising spp24 peptide fragments
granted -
US 8962531
Development of a high-throughput screen for the identification of novel antifungal drug candidates
granted -
US 8962530
Inflammatory bowel disease therapies
granted -
US 8962314
Lateral ventricle cell compositions and use for treating neural degenerative diseases
granted -
US 8962026
Nanoemulsion therapeutic compositions and methods of using the same
granted -
US 8962588
Micro-RNAS that control myosin expression and myofiber identity
granted -
US 8962685
Creatine oral supplementation using creatine hydrochloride salt
granted -
US 8957097
Hemi-phorboxazole A derivatives and methods of their use
granted -
US 8956646
Zwitterionic lipids
granted -
US 8956601
Therapeutic uses of mastic gum fractions
granted -
US 8957031
Competitive inhibitors of invariant chain expression and/or ectopic clip binding
granted -
US 8956616
Constructs binding to phosphatidylserine and their use in disease treatment
granted -
US 8951754
Methods and materials for making simvastatin and related compounds
granted -
US 8952129
Method of treating degenerative diseases
granted -
US 8952025
Multifunctional radical quenchers and their uses
granted -
US 8951794
Methods and compositions for treating neurodegenerative disorders and Alzheimer's disease and improving normal memory
granted -
US 8951551
Multiribbon nanocellulose as a matrix for wound healing
granted -
US 8951503
Optical determination of glucose utilizing boronic acid adducts
granted -
US 8951971
Lymphatic zip codes in tumors and pre-malignant lesions
granted -
US 8945482
System, method and device for tissue-based diagnosis
granted -
US 8948863
Photokinetic ocular drug delivery methods and apparatus
granted -
US 8946424
Deuterated amlexanox
granted -
US 8946391
Construction of a multivalent scFv through alkyne-azide 1,3-dipolar cycloaddition
granted -
US 8946455
Semi-synthetic small molecules for the treatment parasitic disease
granted -
US 8946379
Bladder cancer specific ligand peptides
granted -
US 8946194
One-step processing of hydrogels for mechanically robust and chemically desired features
granted -
US 8946165
Compounds for reversing and inhibiting protein aggregation, and methods for making and using them
granted -
US 8945868
Methods and compositions for modification of a HLA locus
granted -
US 8945602
Porous photonic crystals for drug delivery to the eye
granted -
US 8945595
Insect repellent and attractants
granted -
US 8945587
Synthetic lipid biology for combinatorial engineering of endotoxin
granted -
US 8945508
Dendrimer compositions and methods of synthesis
granted -
US 8945544
Immunogenic compositions comprising progastrin and uses thereof
granted -
US 8945604
Ophthalmic device, and method of use thereof, for increasing ocular boundary lubrication
granted -
US 8946409
Polycyclic Ξ² lactam derivatives for the treatment of cancer
granted -
US 8945858
Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory
granted -
US 8940298
High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
granted -
US 8940711
Micro-RNA family that modulates fibrosis and uses thereof
granted -
US 8940871
Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory